17th Dec 2025 07:00
17 December 2025
CVS GROUP plc
("CVS" or the "Company" and, together with its subsidiaries, the "Group")
Transaction in own shares
CVS announces that on 16 December 2025 it purchased the following number of its ordinary shares of 0.2 pence each ("Ordinary Shares") from Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg"), in accordance with the terms of the share buyback programme announced on 24 October 2025 (the "Share Buyback Programme").
Date of purchase: | 16/12/2025 |
Aggregate number of Ordinary Shares purchased: | 4,432 |
Lowest price paid per share (GBp): | 1,228.00 |
Highest price paid per share (GBp): | 1,248.00 |
Volume weighted average price paid per share (GBp): | 1,240.57 |
CVS intends to cancel all of the purchased Ordinary Shares.
Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 70,821,122 Ordinary Shares in issue and holds no Ordinary Shares in treasury.
The total number of voting rights in CVS is therefore 70,821,122 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.
Since the commencement of the Share Buyback Programme, the Company has repurchased 919,661 Ordinary Shares in aggregate at a weighted average price of 1,216.05 pence per share.
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, the table below contains detailed information of the individual trades made by Berenberg as part of the Share Buyback Programme.
Individual transactions:
Number of Ordinary Shares purchased | Transaction price (GBp share) | Time of transaction (UK Time) | Transaction reference number | Trading Venue |
| |
237 | 1228 | 16/12/2025 08:27:01 | 1352700633551196 | XLON | ||
630 | 1230 | 16/12/2025 11:21:09 | 1352700633561715 | XLON | ||
636 | 1236 | 16/12/2025 13:53:15 | 1352700633570871 | XLON | ||
474 | 1242 | 16/12/2025 14:26:54 | 1352700633573429 | XLON | ||
289 | 1242 | 16/12/2025 14:26:54 | 1352700633573436 | XLON | ||
93 | 1244 | 16/12/2025 14:59:42 | 1352700633578048 | XLON | ||
11 | 1244 | 16/12/2025 15:28:59 | 1352700633582307 | XLON | ||
143 | 1244 | 16/12/2025 15:38:33 | 1352700633583474 | XLON | ||
74 | 1244 | 16/12/2025 15:38:33 | 1352700633583476 | XLON | ||
13 | 1242 | 16/12/2025 15:56:59 | 1352700633586344 | XLON | ||
48 | 1242 | 16/12/2025 15:56:59 | 1352700633586345 | XLON | ||
137 | 1242 | 16/12/2025 15:56:59 | 1352700633586346 | XLON | ||
137 | 1242 | 16/12/2025 15:56:59 | 1352700633586347 | XLON | ||
26 | 1242 | 16/12/2025 15:56:59 | 1352700633586348 | XLON | ||
198 | 1242 | 16/12/2025 16:08:52 | 1352700633589090 | XLON | ||
35 | 1248 | 16/12/2025 16:27:25 | 1352700633593369 | XLON | ||
110 | 1248 | 16/12/2025 16:27:25 | 1352700633593368 | XLON | ||
6 | 1248 | 16/12/2025 16:27:25 | 1352700633593370 | XLON | ||
260 | 1248 | 16/12/2025 16:27:25 | 1352700633593372 | XLON | ||
83 | 1248 | 16/12/2025 16:27:25 | 1352700633593371 | XLON | ||
396 | 1248 | 16/12/2025 16:27:32 | 1352700633593429 | XLON | ||
198 | 1248 | 16/12/2025 16:27:32 | 1352700633593428 | XLON | ||
198 | 1248 | 16/12/2025 16:27:32 | 1352700633593430 | XLON |
Contacts
CVS Group plc via Camarco
Richard Fairman, CEO
Robin Alfonso, CFO
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
Peel Hunt LLP (Nominated Adviser & Joint Broker) +44 (0)20 7418 8900
Christopher Golden / James Steel / Andrew Clark
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Michael Burke / Milo Bonser / Brooke Harris-Lowing
Camarco (Financial PR) [email protected]
Ginny Pulbrook +44 (0)7961 315 138
Letaba Rimell
Tilly Butcher
About CVS Group plc (www.cvsukltd.co.uk)
CVS Group is an AIM-listed provider of veterinary services with operations in the UK and Australia. CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.
The Group now operates c.470 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").
The Group employs c.8,900 personnel, including c.2,400 veterinary surgeons and c.3,300 nurses.
Related Shares:
CVS Group